Sangui BioTech International Inc.: - Granulox(R) - Follow up
11.05.2021 / 11:05
Sangui BioTech:
- Granulox(R) - Follow up
Hamburg, May, 11 2021: With this letter we would like to briefly summarize the events since the acquisition of Sastomed GmbH by the Mölnlycke Health Care Group and point out the latest developments in the Granulox(R) wound spray.
The acquisition of SastoMed GmbH by the Mölnlycke Health Care Group at the end of June 2018 was the starting point for an extensive integration and reorganization program with the target of increasing the market potential of the Granulox(R) wound spray. In addition to adapting the logistical processes, these measures also included legal changes. With the merger of Sastomed GmbH in 2020 with its parent company Mölnylcke Health Care GmbH, Mölnylcke Health Care GmbH is now the contractional licensee of Granulox(R). In addition, extensive and sometimes lengthy restructuring process was carried out in the sales area. The integration of Granulox(R) sales into the sales structure of the Mölnlycke Health Care Group required the reorganization of the partnerships SastoMed GmbH previously entered into in the individual sales territories until 2018. Accordingly, there were temporary slowdown in sales growth in these territories.